Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.